Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial

European Journal of Neurology

Volumn 22, Issue 10, 2015, Pages 1400-1407

  Antonini, A ^a   Bauer, L ^b   Dohin, E ^b   Oertel, W H ^c   Rascol, O ^d   Reichmann, H ^e   Schmid, M ^b   Singh, P ^b   Tolosa, E ^f   Chaudhuri, K Ray ^g  

^a IRCCS SAN CAMILLO HOSPITAL   (Italy)

^b UCB PHARMA   (Belgium)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f UNIVERSITY OF BARCELONA   (Spain)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Non motor symptoms; Non motor symptoms scale; Parkinson's disease; Randomized controlled trial

Indexed keywords

LEVODOPA; PLACEBO; ROTIGOTINE; DOPAMINE RECEPTOR STIMULATING AGENT; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ADVERSE OUTCOME; AGED; APATHY; APPLICATION SITE REACTION; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SYMPTOM; TRANSDERMAL PATCH; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; OUTCOME ASSESSMENT; QUALITY OF LIFE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APATHY; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; QUALITY OF LIFE; TETRAHYDRONAPHTHALENES; THIOPHENES; TRANSDERMAL PATCH;

EID: 84941600813     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12757     Document Type: Article

References (20)

1. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-474.
2. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord 2011; 17: 717-723.
3. Schapira AH. The measurement and importance of non-motor symptoms in Parkinson disease. Eur J Neurol 2015; 22: 2-3.
4. Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009; 24: 1641-1649.
5. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011; 26: 399-406.
6. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 2010; 25: 704-709.
7. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002; 8: 193-197.
8. Antonini A, Albin RL. Dopaminergic treatment and nonmotor features of Parkinson disease: the horse lives. Neurology 2013; 80: 784-785.
9. Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013; 80: 800-809.
10. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006; 21: 916-923.
11. Martinez-Martin P, Rodriguez-Blazquez C, Abe K, et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 2009; 73: 1584-1591.
12. Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007; 22: 1901-1911.
13. Krishnan S, Sarma G, Sarma S, Kishore A. Do nonmotor symptoms in Parkinson's disease differ from normal aging? Mov Disord 2011; 26: 2110-2113.
14. Steiger M, Wong S, Crossley J, Fletcher N, Baker G, Wieshmann U. Are there non-motor symptoms specific to Parkinson's disease? J Neurol Neurosurg Psychiatry 2013; 84: 11e2.
15. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26: 90-99.
16. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573-580.
17. Martinez-Martin P, Reddy P, Antonini A, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis 2011; 1: 197-203.
18. Reddy P, Martinez-Martin P, Rizos A, et al. Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin Neuropharmacol 2012; 35: 205-207.
19. Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord 2015; 30: 510-516.
20. Antonini A, Yegin A, Preda C, Bergmann L, Poewe W. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord 2015; 21: 231-235.